This work not only uncovers the epigenetic regulatory mechanism of tumor cGAS, but also reveals the immunomodulatory roles of VC and TET2 in liver cancer, providing a strategy to induce tumor vascular normalization and a scientific rationale for further clinical trials combining VC with immunotherapy. This evidence concerns the gene TET2 and liver cancer.